Detalhe da pesquisa
1.
Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.
J Pharmacol Exp Ther
; 356(2): 260-6, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26628406
2.
Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension.
CPT Pharmacometrics Syst Pharmacol
; 11(2): 173-184, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34800000
3.
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
J Clin Pharmacol
; 60(7): 915-930, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32080863
4.
Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.
Clin Pharmacol Ther
; 107(1): 246-256, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31356678
5.
Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.
CPT Pharmacometrics Syst Pharmacol
; 8(9): 664-675, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31250974
6.
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Clin Pharmacol Ther
; 104(1): 88-110, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29315504
7.
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
J Clin Pharmacol
; 47(2): 175-86, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17244768
8.
Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease.
J Clin Pharmacol
; 57(6): 739-746, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28144958
9.
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
J Clin Pharmacol
; 54(9): 968-78, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24619932
10.
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
CPT Pharmacometrics Syst Pharmacol
; 8(11): 773-776, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31529677
11.
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.
Drug Metab Pharmacokinet
; 24(1): 53-75, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19252336
12.
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
Br J Clin Pharmacol
; 64(1): 14-26, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17298479